Literature DB >> 20473768

Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma.

Hiromi Kobayashi1, Yuko Minami, Yoichi Anami, Yuzuru Kondou, Tatsuo Iijima, Junko Kano, Yukio Morishita, Koji Tsuta, Shinichiro Hayashi, Masayuki Noguchi.   

Abstract

The GA733 gene family is composed of GA733-1 (TROP2) and GA733-2 (Ep-CAM), whose expression has been examined in various carcinomas and reported to be significantly associated with prognosis. The aim of this study was to investigate the expression of GA733 gene family members and to compare their prognostic significance in pulmonary adenocarcinoma. One hundred thirty paraffin-embedded specimens of small-sized pulmonary adenocarcinoma, less than 2 cm in diameter, were categorized using the classification of small-sized pulmonary adenocarcinoma devised by Noguchi et al. (Cancer 75:2844-2852, 1995) and examined immunohistochemically using a murine monoclonal antibody against Ep-CAM and a goat polyclonal antibody against TROP2. The patient survival rate was calculated using the Kaplan-Meier method. Ep-CAM and TROP2 were similarly expressed in many small-sized pulmonary adenocarcinomas. The expression of Ep-CAM was significantly related to a favorable outcome (p = 0.0185), whereas TROP2 tended to be expressed in cases with an unfavorable outcome (p = 0.0564), and was significantly associated with an unfavorable outcome in nonlepidic-type adenocarcinomas (p = 0.0125). Multivariate analysis showed that TROP2 overexpression and lymph node metastasis were independent prognostic markers. Although the two GA733 proteins share structural similarity, they appear to have opposite biological significances in small-sized adenocarcinomas. As the expression of TROP2 was detected in more poorly differentiated tumors, the protein may have oncogenic activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473768     DOI: 10.1007/s00428-010-0930-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion.

Authors:  S V Litvinov; H A Bakker; M M Gourevitch; M P Velders; S O Warnaar
Journal:  Cell Adhes Commun       Date:  1994-10

2.  Identification of the gene responsible for gelatinous drop-like corneal dystrophy.

Authors:  M Tsujikawa; H Kurahashi; T Tanaka; K Nishida; Y Shimomura; Y Tano; Y Nakamura
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

Review 3.  Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.

Authors:  L S Schwartzberg
Journal:  Crit Rev Oncol Hematol       Date:  2001-10       Impact factor: 6.312

4.  High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl
Journal:  Breast Cancer Res Treat       Date:  2004-08       Impact factor: 4.872

5.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Holger Moch; Patrick A Baeuerle; Elisabeth Mueller-Holzner; Christian Marth; Guenther Gastl; Alain G Zeimet
Journal:  Gynecol Oncol       Date:  2006-05-06       Impact factor: 5.482

Review 6.  The biology of the 17-1A antigen (Ep-CAM).

Authors:  M Balzar; M J Winter; C J de Boer; S V Litvinov
Journal:  J Mol Med (Berl)       Date:  1999-10       Impact factor: 4.599

7.  Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival.

Authors:  Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

8.  Retroposition in a family of carcinoma-associated antigen genes.

Authors:  A J Linnenbach; B A Seng; S Wu; S Robbins; M Scollon; J J Pyrc; T Druck; K Huebner
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

9.  Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer.

Authors:  I Songun; S V Litvinov; C J H van de Velde; S T Pals; J Hermans; J H J M van Krieken
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

10.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

Authors:  D Fong; P Moser; C Krammel; J M Gostner; R Margreiter; M Mitterer; G Gastl; G Spizzo
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  15 in total

1.  siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells.

Authors:  Xiao-Yan Gao; Ye-Han Zhu; Li-Xin Zhang; Hui-Yu Lu; Ai-Gui Jiang
Journal:  Exp Ther Med       Date:  2015-05-28       Impact factor: 2.447

2.  Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer.

Authors:  Faruk Tas; Senem Karabulut; Derya Duranyildiz
Journal:  Mol Cell Biochem       Date:  2014-07-25       Impact factor: 3.396

3.  Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.

Authors:  Shota Omori; Koji Muramatsu; Takuya Kawata; Eriko Miyawaki; Taichi Miyawaki; Nobuaki Mamesaya; Takahisa Kawamura; Haruki Kobayashi; Kazuhisa Nakashima; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Takashi Sugino; Toshiaki Takahashi
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-17       Impact factor: 4.322

4.  TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors.

Authors:  Shailendra Kapoor
Journal:  Tumour Biol       Date:  2012-11-13

5.  TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma.

Authors:  Jau-Chen Lin; Yi-Ying Wu; Jing-Yi Wu; Tzu-Chieh Lin; Chen-Tu Wu; Yih-Leong Chang; Yuh-Shan Jou; Tse-Ming Hong; Pan-Chyr Yang
Journal:  EMBO Mol Med       Date:  2012-03-15       Impact factor: 12.137

6.  Significance of EpCAM and TROP2 expression in non-small cell lung cancer.

Authors:  Min Gyoung Pak; Dong Hoon Shin; Chang Hun Lee; Min Ki Lee
Journal:  World J Surg Oncol       Date:  2012-04-06       Impact factor: 2.754

Review 7.  Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.

Authors:  Anna Shvartsur; Benjamin Bonavida
Journal:  Genes Cancer       Date:  2015-03

8.  MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer.

Authors:  Ning Zhou; Haijuan Wang; Hongxu Liu; Hongsheng Xue; Feng Lin; Xiting Meng; Ailing Liang; Zhilong Zhao; YongJun Liu; Haili Qian
Journal:  J Exp Clin Cancer Res       Date:  2015-12-23

Review 9.  Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis.

Authors:  Ping Zeng; Min-Bin Chen; Li-Na Zhou; Min Tang; Chao-Ying Liu; Pei-Hua Lu
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

10.  Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma.

Authors:  Aigui Jiang; Xiaoyan Gao; Degeng Zhang; Lixin Zhang; Huiyu Lu
Journal:  Oncol Lett       Date:  2013-05-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.